These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
3. Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up. Nakagawa T; Kami M; Hori A; Kim SW; Murashige N; Hamaki T; Kishi Y; Fujimoto H; Matsuoka N; Okajima E; Komiyama M; Tobisu K; Wakayama T; Uike N; Tajima K; Makimoto A; Mori S; Tanosaki R; Takaue Y; Kakizoe T Exp Hematol; 2004 Jul; 32(7):599-606. PubMed ID: 15246155 [TBL] [Abstract][Full Text] [Related]
4. [Reduced-intensity allogeneic hematopoietic stem cell transplantation (mini-transplantation) for solid tumors]. Makimoto A; Takaue Y Gan To Kagaku Ryoho; 2002 Jun; 29(6):835-41. PubMed ID: 12090032 [TBL] [Abstract][Full Text] [Related]
5. Development of reduced-intensity hematopoietic stem cell transplantation in the National Cancer Center Hospital, Japan. Kami M; Takaue Y Ther Apher Dial; 2003 Jun; 7(3):318-28. PubMed ID: 12924607 [TBL] [Abstract][Full Text] [Related]
6. Relationship between tumor-infiltrating T lymphocytes and clinical response after reduced-intensity allogeneic hematopoietic stem cell transplantation for advanced renal cell carcinoma: a single center prospective study. Ishiyama K; Takami A; Suzuki S; Konaka H; Namiki M; Ooi A; Nakao S Jpn J Clin Oncol; 2009 Dec; 39(12):807-12. PubMed ID: 19770130 [TBL] [Abstract][Full Text] [Related]
8. [Allogeneic hematopoietic stem cell transplantation for solid tumors in the United States: a review]. Cheng YC; Ueno NT Nihon Rinsho; 2003 Sep; 61(9):1619-34. PubMed ID: 14515734 [TBL] [Abstract][Full Text] [Related]
9. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease. Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664 [TBL] [Abstract][Full Text] [Related]
10. [Allogeneic hematopoietic stem cell transplantation for solid tumors]. Kanda Y Rinsho Ketsueki; 2004 Mar; 45(3):189-94. PubMed ID: 15103931 [No Abstract] [Full Text] [Related]
11. Allogeneic stem cell transplantation after reduced-intensity conditioning in lymphoid malignancies. Sureda A; Schmitz N Ann Hematol; 2003 Jan; 82(1):1-13. PubMed ID: 12574957 [TBL] [Abstract][Full Text] [Related]
12. [Allogeneic hematopoietic cell transplantation in solid tumors]. Bay JO; Choufi B; Tournilhac O; Faucher C; Blaise D Bull Cancer; 2001 Sep; 88(9):900-7. PubMed ID: 11604364 [TBL] [Abstract][Full Text] [Related]
13. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases. Resnick IB; Shapira MY; Slavin S Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565 [TBL] [Abstract][Full Text] [Related]
14. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Demirer T; Barkholt L; Blaise D; Pedrazzoli P; Aglietta M; Carella AM; Bay JO; Arpaci F; Rosti G; Gurman G; Niederwieser D; Bregni M; Nat Clin Pract Oncol; 2008 May; 5(5):256-67. PubMed ID: 18398414 [TBL] [Abstract][Full Text] [Related]
15. Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma. Nelson RP; Logan TF; Abonour R Bone Marrow Transplant; 2002 Dec; 30(12):805-12. PubMed ID: 12476272 [TBL] [Abstract][Full Text] [Related]
16. Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen. Maruyama D; Fukuda T; Kato R; Yamasaki S; Usui E; Morita-Hoshi Y; Kim SW; Mori S; Heike Y; Makimoto A; Tajima K; Tanosaki R; Tobinai K; Takaue Y Biol Blood Marrow Transplant; 2007 Aug; 13(8):932-41. PubMed ID: 17640597 [TBL] [Abstract][Full Text] [Related]
17. Reduced-intensity unrelated cord blood transplantation for treatment of metastatic renal cell carcinoma: first evidence of cord-blood-versus-solid-tumor effect. Takami A; Takamatsu H; Yamazaki H; Ishiyama K; Okumura H; Ohata K; Konaka H; Asakura H; Namiki M; Nakao S Bone Marrow Transplant; 2006 Dec; 38(11):729-32. PubMed ID: 17028623 [TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic stem-cell transplantation: the next generation of therapy for metastatic renal cell cancer. Arya M; Chao D; Patel HR Nat Clin Pract Oncol; 2004 Nov; 1(1):32-8. PubMed ID: 16264797 [TBL] [Abstract][Full Text] [Related]
19. Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor. Eto M; Kamiryo Y; Takeuchi A; Harano M; Tatsugami K; Harada M; Kiyoshima K; Hamaguchi M; Teshima T; Tsuneyoshi M; Yoshikai Y; Naito S Clin Cancer Res; 2008 May; 14(9):2833-40. PubMed ID: 18451251 [TBL] [Abstract][Full Text] [Related]